Javascript must be enabled to continue!
Abstract 12225: Effects of Obesity on Noninvasive Testing and Angiography Results in Patients With Suspected Cardiac Ischemia: Insights From the PROMISE Trial
View through CrossRef
Background:
Evaluation of obese patients with suspected CAD is challenging because obesity is a CV risk factor, but adiposity itself may mimic symptoms of CAD and reduce the accuracy of diagnostic testing. Optimal testing strategies in obese patients are not known.
Methods:
Patients with stable symptoms suggestive of cardiac ischemia from the PROMISE trial (n=9230) were classified according to BMI. Providers specified a functional test modality prior to stratified randomization to functional (stress testing) or anatomical (CTA) testing. We assessed relationships between BMI, physician’s preference of functional test, test positivity and results of catheter angiography (cath) using logistic regression.
Results:
Providers were more likely to choose SPECT over other functional tests as BMI increased (OR 1.04 per unit increase in BMI above 27, p<0.001). In patients with BMI ≥ 35 vs. < 35, the rate of positivity with CTA was similar (10% vs. 12%; see Table). The same was true for stress echo and stress ECG (positivity 8-13%, p>0.8 for both). In contrast, SPECT was significantly more likely to be positive in those with BMI ≥ 35 vs. <35 (18% vs. 13%; p=0.001). The likelihood of finding obstructive CAD at cath did not differ with BMI ≥ 35 vs. <35 in patients having CTA (59% vs. 52%, p=0.22), but among SPECT patients, positivity was only 29% with BMI ≥ 35 compared to 52% with BMI < 35 (p=0.005; Table).
Conclusions:
Increasing levels of obesity were associated with stronger physician preference for SPECT over other noninvasive tests. In patients receiving SPECT, higher levels of obesity were associated with a higher rate of positive results, but a lower cath yield for obstructive CAD. In contrast, in patients receiving CTA, positivity rates and cath yield did not vary by BMI. Obesity appears to significantly influence provider decision-making with regard to noninvasive test choice, probability of abnormal test results and probability of finding obstructive disease at cath.
Ovid Technologies (Wolters Kluwer Health)
Title: Abstract 12225: Effects of Obesity on Noninvasive Testing and Angiography Results in Patients With Suspected Cardiac Ischemia: Insights From the PROMISE Trial
Description:
Background:
Evaluation of obese patients with suspected CAD is challenging because obesity is a CV risk factor, but adiposity itself may mimic symptoms of CAD and reduce the accuracy of diagnostic testing.
Optimal testing strategies in obese patients are not known.
Methods:
Patients with stable symptoms suggestive of cardiac ischemia from the PROMISE trial (n=9230) were classified according to BMI.
Providers specified a functional test modality prior to stratified randomization to functional (stress testing) or anatomical (CTA) testing.
We assessed relationships between BMI, physician’s preference of functional test, test positivity and results of catheter angiography (cath) using logistic regression.
Results:
Providers were more likely to choose SPECT over other functional tests as BMI increased (OR 1.
04 per unit increase in BMI above 27, p<0.
001).
In patients with BMI ≥ 35 vs.
< 35, the rate of positivity with CTA was similar (10% vs.
12%; see Table).
The same was true for stress echo and stress ECG (positivity 8-13%, p>0.
8 for both).
In contrast, SPECT was significantly more likely to be positive in those with BMI ≥ 35 vs.
<35 (18% vs.
13%; p=0.
001).
The likelihood of finding obstructive CAD at cath did not differ with BMI ≥ 35 vs.
<35 in patients having CTA (59% vs.
52%, p=0.
22), but among SPECT patients, positivity was only 29% with BMI ≥ 35 compared to 52% with BMI < 35 (p=0.
005; Table).
Conclusions:
Increasing levels of obesity were associated with stronger physician preference for SPECT over other noninvasive tests.
In patients receiving SPECT, higher levels of obesity were associated with a higher rate of positive results, but a lower cath yield for obstructive CAD.
In contrast, in patients receiving CTA, positivity rates and cath yield did not vary by BMI.
Obesity appears to significantly influence provider decision-making with regard to noninvasive test choice, probability of abnormal test results and probability of finding obstructive disease at cath.
Related Results
Effects of simulated ischemia-reperfusion and atorvastatin on INa in rat left ventricular myocytes.
Effects of simulated ischemia-reperfusion and atorvastatin on INa in rat left ventricular myocytes.
Objective
To observe time dependent effects of simulated ischemia-reperfusion on transient sodium currents (INa) in rat left ventricular myocytes, and effects of ...
Ischemia-Guided Coronary Revascularization Following Lower-Extremity Revascularization Improves 5-Year Survival of Patients With Chronic Limb-Threatening Ischemia
Ischemia-Guided Coronary Revascularization Following Lower-Extremity Revascularization Improves 5-Year Survival of Patients With Chronic Limb-Threatening Ischemia
Purpose:
To determine whether diagnosis of asymptomatic (silent) coronary ischemia using coronary computed tomography (CT)-derived fracti...
Noninvasive ventilation vs. high-flow nasal cannula oxygen for preoxygenation before intubation in patients with obesity: a post hoc analysis of a randomized controlled trial
Noninvasive ventilation vs. high-flow nasal cannula oxygen for preoxygenation before intubation in patients with obesity: a post hoc analysis of a randomized controlled trial
Abstract
Background
Critically ill patients with obesity may have an increased risk of difficult intubation and subsequen...
Emerging Evidence of IgG4-Related Disease in Pericarditis: A Systematic Review
Emerging Evidence of IgG4-Related Disease in Pericarditis: A Systematic Review
Abstract
Introduction
Immunoglobulin G4-related disease (IgG4-RD) is a recently identified immune-mediated condition that is debilitating and often overlooked. While IgG4-RD has be...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
Incidence of Venous Thromboembolism in Patients with Different Classes of Obesity in Comparison to Inherited Thrombophilias
Incidence of Venous Thromboembolism in Patients with Different Classes of Obesity in Comparison to Inherited Thrombophilias
Introduction: Obesity is a significant risk factor for venous thromboembolism (VTE). It is linked to physical inactivity, increased intra-abdominal pressure, chronic inflammation, ...
International Breast Cancer Study Group (IBCSG)
International Breast Cancer Study Group (IBCSG)
This section provides current contact details and a summary of recent or ongoing clinical trials being coordinated by International Breast Cancer Study Group (IBCSG). Clinical tria...
Abstract SY38-02: Clinical investigations of obesity in cancer: BMI and other confounders
Abstract SY38-02: Clinical investigations of obesity in cancer: BMI and other confounders
Abstract
Obesity has been linked with increased incidence and worse outcomes of at least 13 human cancers. For other cancers, our understanding of their relationship...

